Please provide your email address to receive an email when new articles are posted on . At week 28, 88% of patients treated with combination therapy achieved 75% disease severity reduction vs. 47% on ...

Please provide your email address to receive an email when new articles are posted on . The standardized overall prevalence rate of lichen planus was 0.15%. Among those treated with systemic ...

AMSTERDAM — Treatment with ruxolitinib cream, 1.5%, achieved rapid and marked reductions in the clinical signs and symptoms of cutaneous lichen planus, including itch and skin pain, both when given ...

PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies ...

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today ...

Oral Lichen Planus: Causes, Symptoms, Treatment, and Prevention: By Anjali Srivastava Oral Lichen Planus is a long-term inflammatory condition that affects the soft tissues inside the mouth, often ...

When your mouth hurts, it’s so uncomfortable that it’s hard to enjoy a meal and sometimes even sleep. You can try something like oral numbing gels or salt-water rinses, but if it doesn’t go away you ...

Lipella Pharmaceuticals Inc. announced that the FDA has approved an Expanded Access Program for LP-310, an oral rinse formulated to treat oral lichen planus (OLP), a debilitating condition affecting ...

Oral lichen planus (OLP) is a chronic, immune‐mediated mucosal disorder characterised by a range of clinical presentations, from asymptomatic reticular patterns to painful erosive lesions. The ...